All stock lists
Unlock the score
Femasys Inc (NASDAQ:FEMY)
US · Delayed Price · Currency is USD
Healthcare · Medical - Instruments & Supplies
1.46-0.04 (-2.67%)
Market cap
$12.2M
Insider Score
Health Score
Analyst consensus
Listed since
Jun 18, 2021
Website
Insider Score
/ 100
FEMY Insider Score
FEMASYS INC has a live Insider Score.
Scored on 5 qualifying trades from 5 insiders in the last 90 days.
Financial Health Score
Weak
From FEMY’s reported statements · Q2 2026 (trailing 12 months)
Profitability0 / 20
Loses money on what it sells.
- Revenue
- $2.3M
- Net income
- -$12.3M
- Net margin
- -534.3%
Leverage8 / 20
A manageable debt load.
- Total debt
- $4.8M
- Cash
- $1.4M
- Debt / equity
- 1.19
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $8.3M
- Current liabilities
- $3.9M
- Current ratio
- 2.14
Cash generation0 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$17.7M
- Free cash flow
- -$18.1M
- FCF margin
- -788.0%
Dilution & runway0 / 20
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 3.4M
- Share growth (1y)
- 132.5%
- Cash runway
- 1 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
FEMY Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 331.83 K | 424.89 K | 813.39 K | 729.39 K | 409.27 K | 341.26 K |
| Revenue Growth (YoY) | -18.92 % | 24.50 % | 39.86 % | 31.44 % | 84.78 % | 25.86 % |
| Cost of Revenue | 359.06 K | 359.06 K | -122.85 K | 504.91 K | 373.07 K | 117.27 K |
| Gross Profit | -27.23 K | 65.83 K | 936.24 K | 224.48 K | 36.20 K | 224.00 K |
| SG&A Expense | 3.23 M | 3.10 M | 3.24 M | 2.62 M | 2.60 M | 2.63 M |
| R&D Expense | 1.95 M | 1.31 M | 1.81 M | 1.38 M | 1.41 M | 2.97 M |
| Operating Expenses | 5.04 M | 4.29 M | 5.56 M | 3.88 M | 3.89 M | 5.68 M |
| Operating Income | -5.07 M | -4.22 M | -4.62 M | -3.65 M | -3.85 M | -5.46 M |
| Pretax Income | -4.47 M | 846.10 K | -3.94 M | -4.19 M | -4.59 M | -5.90 M |
| Tax Provision | 865.00 | 517.45 K | 5.49 K | 0.00 | 0.00 | -4.19 K |
| Net Income | -4.47 M | 328.65 K | -3.95 M | -4.19 M | -4.59 M | -5.90 M |
| EPS (Basic) | -1.33 | 0.10 | -1.33 | -2.00 | -3.20 | -4.60 |
| EPS (Diluted) | -1.33 | 0.08 | -1.33 | -2.00 | -3.20 | -4.60 |
| Shares Outstanding | 3.36 M | 3.33 M | 1.98 M | 1.44 M | 1.44 M | 1.26 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.